Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers

Ongoing pharmaceutical reforms in France

(2013) Catherine Sermet et al.   Applied Health Economics and Health Policy

Informing disinvestment through cost-effectiveness modelling

(2012) Jonathan Karnon et al.   Applied Health Economics and Health Policy

Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme

(2010) Jane Robertson et al.   Australian Health Review

Patient access schemes for high-cost cancer medicines

(2010) Steve Williamson   LANCET ONCOLOGY

Access with Evidence Development

(2010) Penny E. Mohr et al.   PHARMACOECONOMICS

Access with Evidence Development in the UK

(2010) Andrew Briggs et al.   PHARMACOECONOMICS

Canʼt Get No Satisfaction? Will Pay for Performance Help?

(2010) Adrian Towse et al.   PHARMACOECONOMICS

Funding the Unfundable

(2010) Tania Stafinski et al.   PHARMACOECONOMICS

Access with Evidence Development Schemes

(2010) Christopher J. McCabe et al.   PHARMACOECONOMICS

Using Effectiveness and Cost-effectiveness to Make Drug Coverage Decisions

(2009) Fiona M. Clement et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Pharmaceutical Risk-Sharing Agreements

(2009) Joseph P Cook et al.   PHARMACOECONOMICS

Having Your Cake and Eating It

(2009) Brian Godman et al.   PHARMACOECONOMICS

Recent National and Regional Drug Reforms in Sweden

(2009) Björn Wettermark et al.   PHARMACOECONOMICS

Update of Recent Reforms in Germany to Enhance the Quality and Efficiency of Prescribing of Proton Pump Inhibitors and Lipid-Lowering Drugs

(2009) Brian Godman et al.   PHARMACOECONOMICS

Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance

(2009) Brian Godman et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future

(2009) Brian Godman et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Bevacizumab in advanced cancer, too much or too little?

(2008) A. Jirillo et al.   ANNALS OF ONCOLOGY

Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective

(2008) C. McCabe et al.   ANNALS OF ONCOLOGY

Risk Sharing and Payment by Results

(2008) A Breckenridge et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Enhancing the rational use of new medicines across European health care systems

(2008) Silvio Garattini et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Tier 4 Drugs and the Fraying of the Social Compact

(2008) Thomas H. Lee et al.   NEW ENGLAND JOURNAL OF MEDICINE

Balancing Big Pharma’s books

(2008) Andrew Jack   BMJ-British Medical Journal

Insight into recent reforms and initiatives in Austria: implications for key stakeholders

(2008) Brian Godman et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Prices and distribution margins of in-patent drugs in pharmacy: A comparison in seven European countries

(2007) Livio Garattini et al.   HEALTH POLICY